Skip to main content Accessibility help

Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study

  • Christian A. Webb (a1), Madhukar H. Trivedi (a2), Zachary D. Cohen (a3), Daniel G. Dillon (a1), Jay C. Fournier (a4), Franziska Goer (a1), Maurizio Fava (a5), Patrick J. McGrath (a6), Myrna Weissman (a6), Ramin Parsey (a7), Phil Adams (a6), Joseph M. Trombello (a2), Crystal Cooper (a2), Patricia Deldin (a8), Maria A. Oquendo (a3), Melvin G. McInnis (a8), Quentin Huys (a9), Gerard Bruder (a6), Benji T. Kurian (a2), Manish Jha (a2), Robert J. DeRubeis (a3) and Diego A. Pizzagalli (a1)...



Major depressive disorder (MDD) is a highly heterogeneous condition in terms of symptom presentation and, likely, underlying pathophysiology. Accordingly, it is possible that only certain individuals with MDD are well-suited to antidepressants. A potentially fruitful approach to parsing this heterogeneity is to focus on promising endophenotypes of depression, such as neuroticism, anhedonia, and cognitive control deficits.


Within an 8-week multisite trial of sertraline v. placebo for depressed adults (n = 216), we examined whether the combination of machine learning with a Personalized Advantage Index (PAI) can generate individualized treatment recommendations on the basis of endophenotype profiles coupled with clinical and demographic characteristics.


Five pre-treatment variables moderated treatment response. Higher depression severity and neuroticism, older age, less impairment in cognitive control, and being employed were each associated with better outcomes to sertraline than placebo. Across 1000 iterations of a 10-fold cross-validation, the PAI model predicted that 31% of the sample would exhibit a clinically meaningful advantage [post-treatment Hamilton Rating Scale for Depression (HRSD) difference ⩾3] with sertraline relative to placebo. Although there were no overall outcome differences between treatment groups (d = 0.15), those identified as optimally suited to sertraline at pre-treatment had better week 8 HRSD scores if randomized to sertraline (10.7) than placebo (14.7) (d = 0.58).


A subset of MDD patients optimally suited to sertraline can be identified on the basis of pre-treatment characteristics. This model must be tested prospectively before it can be used to inform treatment selection. However, findings demonstrate the potential to improve individual outcomes through algorithm-guided treatment recommendations.


Corresponding author

Author for correspondence: Christian A. Webb, E-mail:


Hide All
American Psychiatric Association (2010) Treatment of Patients with major Depressive Disorder. 3rd Edn. Washington, DC: American Psychiatric Press.
Austin, PC and Tu, JV (2004) Bootstrap methods for developing predictive models. The American Statistician 58, 131137.
Bagby, RM, Quilty, LC, Segal, ZV, McBride, CC, Kennedy, SH and Costa, PT (2008) Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. The Canadian Journal of Psychiatry 53, 361370.
Baldessarini, RJ, Forte, A, Selle, V, Sim, K, Tondo, L, Undurraga, J and Vázquez, GH (2017) Morbidity in depressive disorders. Psychotherapy and Psychosomatics 86, 6572.
Ball, S, Classi, P and Dennehy, EB (2014) What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment. Annals of General Psychiatry 13, 8.
Bet, PM, Hugtenburg, JG, Penninx, BWJH and Hoogendijk, WJG (2013) Side effects of antidepressants during long-term use in a naturalistic setting. European Neuropsychopharmacology 23, 14431451.
Cipriani, A, Furukawa, TA, Salanti, G, Chaimani, A, Atkinson, LZ, Ogawa, Y, Leucht, S, Ruhe, HG, Turner, EH, Higgins, JPT, Egger, M, Takeshima, N, Hayasaka, Y, Imai, H, Shinohara, K, Tajika, A, Ioannidis, JPA and Geddes, JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet 391, 13571366.
Cohen, ZD and DeRubeis, RJ (2018) Treatment selection in depression. Annual Review of Clinical Psychology 14, 209236.
Cohen, ZD, Kim, T, Van, H, Dekker, J and Driessen, E (2017) Recommending cognitive-behavioral versus psychodynamic therapy for mild to moderate adult depression. PsyArXiv,
DeRubeis, RJ, Cohen, ZD, Forand, NR, Fournier, JC, Gelfand, LA and Lorenzo-Luaces, L (2014) The personalized advantage index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS ONE 9, e83875.
Dunner, DL (2001) Acute and maintenance treatment of chronic depression. The Journal of Clinical Psychiatry 62(Suppl. 6), 1016.
Eriksen, BA and Eriksen, CW (1974) Effects of noise letters upon the identification of a target letter in a nonsearch task. Perception & Psychophysics 16, 143149.
Etkin, A, Patenaude, B, Song, YJC, Usherwood, T, Rekshan, W, Schatzberg, AF, Rush, AJ and Williams, LM (2015) A cognitive–emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology 40, 13321342.
Fava, M, Rush, AJ, Alpert, JE, Balasubramani, GK, Wisniewski, SR, Carmin, CN, Biggs, MM, Zisook, S, Leuchter, A, Howland, R, Warden, D and Trivedi, MH (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. American Journal of Psychiatry 165, 342351.
Fiedler, K (2011) Voodoo correlations are everywhere – not only in neuroscience. Perspectives on Psychological Science 6, 163171.
Fournier, JC, DeRubeis, RJ, Hollon, SD, Dimidjian, S, Amsterdam, JD, Shelton, RC and Fawcett, J (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303, 4753.
Fournier, JC, DeRubeis, RJ, Hollon, SD, Gallop, R, Shelton, RC and Amsterdam, JD (2013) Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behaviour Research and Therapy 51, 392398.
Fournier, JC, DeRubeis, RJ, Shelton, RC, Hollon, SD, Amsterdam, JD and Gallop, R (2009) Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. Journal of Consulting and Clinical Psychology 77, 775787.
Fried, EI and Nesse, RM (2015 a) Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. Journal of Affective Disorders 172, 96102.
Fried, EI and Nesse, RM (2015 b) Depression sum-scores don't add up: why analyzing specific depression symptoms is essential. BMC Medicine 13, 72.
Friedman, J, Hastie, T and Tibshirani, R (2010) Regularization paths for generalized linear models via coordinate descent. Journal of Statistical Software 33, 122.
Garge, NR, Bobashev, G and Eggleston, B (2013) Random forest methodology for model-based recursive partitioning: the mobForest package for R. BMC Bioinformatics 14, 125.
Gillan, CM and Whelan, R (2017) What big data can do for treatment in psychiatry. Current Opinion in Behavioral Sciences 18, 3442.
Goldstein, BL and Klein, DN (2014) A review of selected candidate endophenotypes for depression. Clinical Psychology Review 34, 417427.
Gottesman, II and Gould, TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. The American Journal of Psychiatry 160, 636645.
Hamilton, M (1960) A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 23, 5662.
Hastie, T, Tibshirani, R and Friedman, J (2009) The Elements of Statistical Learning: Data Mining, Inference, and Prediction, Second Edition. 2nd Edn. New York, NY: Springer.
Herrera-Guzmán, I, Gudayol-Ferré, E, Herrera-Guzmán, D, Guàrdia-Olmos, J, Hinojosa-Calvo, E and Herrera-Abarca, JE (2009) Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. Journal of Psychiatric Research 43, 855863.
Hollon, SD (2016) The efficacy and acceptability of psychological interventions for depression: where we are now and where we are going. Epidemiology and Psychiatric Sciences 25, 295300.
Holmes, AJ, Bogdan, R and Pizzagalli, DA (2010) Serotonin transporter genotype and action monitoring dysfunction: a possible substrate underlying increased vulnerability to depression. Neuropsychopharmacology 35, 11861197.
Huibers, MJH, Cohen, ZD, Lemmens, LHJM, Arntz, A, Peeters, FPML, Cuijpers, P and DeRubeis, RJ (2015) Predicting optimal outcomes in cognitive therapy or interpersonal psychotherapy for depressed individuals using the personalized advantage index approach. PLoS ONE 10, e0140771.
Jakobsen, JC, Katakam, KK, Schou, A, Hellmuth, SG, Stallknecht, SE, Leth-Møller, K, Iversen, M, Banke, MB, Petersen, IJ, Klingenberg, SL, Krogh, J, Ebert, SE, Timm, A, Lindschou, J and Gluud, C (2017) Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 17, 58.
Jakubovski, E and Bloch, MH (2014) Prognostic subgroups for citalopram response in the STAR*D trial. The Journal of Clinical Psychiatry 75, 738747.
Julien, RM (2013) A Primer of Drug Action: A Concise Nontechnical Guide to the Actions, Uses, and Side Effects of Psychoactive Drugs, Revised and Updated. New York: Henry Holt and Company.
Kapelner, A and Bleich, J (2016) Bartmachine: machine learning with Bayesian additive regression trees. Journal of Statistical Software 70, 140.
Khan, A, Dager, SR, Cohen, S, Avery, DH, Scherzo, B and Dunner, DL (1991) Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 4, 125130.
Khan, A, Leventhal, RM, Khan, SR and Brown, WA (2002) Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 22, 4045.
Khin, NA, Chen, Y-F, Yang, Y, Yang, P and Laughren, TP (2011) Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US food and drug administration in support of new drug applications. The Journal of Clinical Psychiatry 72, 464472.
Kirsch, I (2015) Clinical trial methodology and drug-placebo differences. World Psychiatry 14, 301302.
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ and Johnson, BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Medicine 5, e45.
Kraemer, HC (2013) Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach. Statistics in Medicine 32, 19641973.
Kraemer, HC and Blasey, CM (2004) Centring in regression analyses: a strategy to prevent errors in statistical inference. International Journal of Methods in Psychiatric Research 13, 141151.
Lam, RW, Kennedy, SH, McIntyre, RS and Khullar, A (2014) Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. The Canadian Journal of Psychiatry 59, 649654.
Leucht, S, Hierl, S, Kissling, W, Dold, M and Davis, JM (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. The British Journal of Psychiatry 200, 97106.
Mahableshwarkar, AR, Zajecka, J, Jacobson, W, Chen, Y and Keefe, RS (2015) A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 40, 20252037.
Marcus, SC, Hassan, M and Olfson, M (2009) Antidepressant switching among adherent patients treated for depression. Psychiatric Services 60, 617623.
Mars, B, Heron, J, Gunnell, D, Martin, RM, Thomas, KH and Kessler, D (2017) Prevalence and patterns of antidepressant switching amongst primary care patients in the UK. Journal of Psychopharmacology 31, 553560.
McCrae, RR and Costa, PT (2010) NEO Inventories Professional Manual. Lutz, FL: Psychological Assessment Resources.
McGrath, CL, Kelley, ME, Holtzheimer, PE, Dunlop, BW, Craighead, WE, Franco, AR, Craddock, RC and Mayberg, HS (2013) Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 70, 821829.
McMakin, DL, Olino, TM, Porta, G, Dietz, LJ, Emslie, G, Clarke, G, Wagner, KD, Asarnow, JR, Ryan, ND, Birmaher, B, Shamseddeen, W, Mayes, T, Kennard, B, Spirito, A, Keller, M, Lynch, FL, Dickerson, JF and Brent, DA (2012) Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor-treatment resistant depression. Journal of the American Academy of Child and Adolescent Psychiatry 51, 404411.
Milea, D, Guelfucci, F, Bent-Ennakhil, N, Toumi, M and Auray, J-P (2010) Antidepressant monotherapy: a claims database analysis of treatment changes and treatment duration. Clinical Therapeutics 32, 20572072.
Moncrieff, J and Kirsch, I (2015) Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemporary Clinical Trials 43, 6062.
Moncrieff, J, Wessely, S and Hardy, R (2004) Active placebos versus antidepressants for depression. The Cochrane Library.
NICE (2018) Depression in adults: recognition and management|guidance and guidelines|NICE.
Pizzagalli, DA, Evins, AE, Schetter, EC, Frank, MJ, Pajtas, PE, Santesso, DL and Culhane, M (2008a) Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology 196, 221232.
Pizzagalli, DA, Goetz, E, Ostacher, M, Iosifescu, DV and Perlis, RH (2008b) Euthymic patients with bipolar disorder show decreased reward learning in a probabilistic reward task. Biological Psychiatry 64, 162168.
Pizzagalli, DA, Jahn, AL and O'Shea, JP (2005) Toward an objective characterization of an anhedonic phenotype: a signal-detection approach. Biological Psychiatry 57, 319327.
Pizzagalli, DA, Webb, CA, Dillon, DG, Tenke, CE, Kayser, J, Goer, F, Fava, M, McGrath, P, Weissman, M, Parsey, R, Adams, P, Trombello, J, Cooper, C, Deldin, P, Oquendo, MA, McInnis, MG, Carmody, T, Bruder, G and Trivedi, MH (2018) Pretreatment rostral anterior cingulate cortex theta activity in relation to symptom improvement in depression: a randomized clinical trial. JAMA Psychiatry 75, 547554.
Quilty, LC, Meusel, L-AC and Bagby, RM (2008) Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. Journal of Affective Disorders 111, 6773.
R Core Team (2013) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
Rush, AJ, Trivedi, MH, Ibrahim, HM, Carmody, TJ, Arnow, B, Klein, DN, Markowitz, JC, Ninan, PT, Kornstein, S, Manber, R, Thase, ME, Kocsis, JH and Keller, MB (2003) The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573583.
Rush, AJ, Trivedi, MH, Wisniewski, SR, Nierenberg, AA, Stewart, JW, Warden, D, Niederehe, G, Thase, ME, Lavori, PW, Lebowitz, BD, McGrath, PJ, Rosenbaum, JF, Sackeim, HA, Kupfer, DJ, Luther, J and Fava, M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. The American Journal of Psychiatry 163, 19051917.
Saragoussi, D, Chollet, J, Bineau, S, Chalem, Y and Milea, D (2012) Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) Study. International Journal of Clinical Practice 66, 10791087.
Schultz, J and Joish, V (2009) Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatric Services 60, 16041611.
Snaith, RP, Hamilton, M, Morley, S, Humayan, A, Hargreaves, D and Trigwell, P (1995) A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale. British Journal of Psychiatry 167, 99103.
Soskin, DP, Carl, JR, Alpert, J and Fava, M (2012) Antidepressant effects on emotional temperament: toward a biobehavioral research paradigm for major depressive disorder. CNS Neuroscience & Therapeutics 18, 441451.
Souery, D, Oswald, P, Massat, I, Bailer, U, Bollen, J, Demyttenaere, K, Kasper, S, Lecrubier, Y, Montgomery, S, Serretti, A, Zohar, J and Mendlewicz, J, Group for the Study of Resistant Depression (2007) Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. The Journal of Clinical Psychiatry 68, 10621070.
Stekhoven, DJ and Bühlmann, P (2012) Missforest – non-parametric missing value imputation for mixed-type data. Bioinformatics (Oxford, England) 28, 112118.
Tang, TZ, DeRubeis, RJ, Hollon, SD, Amsterdam, J, Shelton, R and Schalet, B (2009) Personality change during depression treatment: a placebo-controlled trial. Archives of General Psychiatry 66, 13221330.
Thomas, L, Kessler, D, Campbell, J, Morrison, J, Peters, TJ, Williams, C, Lewis, G and Wiles, N (2013) Prevalence of treatment-resistant depression in primary care: cross-sectional data. The British Journal of General Practice 63, e852e858.
Trivedi, MH, McGrath, PJ, Fava, M, Parsey, RV, Kurian, BT, Phillips, ML, Oquendo, MA, Bruder, G, Pizzagalli, D, Toups, M, Cooper, C, Adams, P, Weyandt, S, Morris, DW, Grannemann, BD, Ogden, RT, Buckner, R, McInnis, M, Kraemer, HC, Petkova, E, Carmody, TJ and Weissman, MM (2016) Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design. Journal of Psychiatric Research 78, 1123.
Trivedi, MH, Rush, AJ, Wisniewski, SR, Nierenberg, AA, Warden, D, Ritz, L, Norquist, G, Howland, RH, Lebowitz, B, McGrath, PJ, Shores-Wilson, K, Biggs, MM, Balasubramani, GK and Fava, M (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 2840.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA and Rosenthal, R (2008) Selective publication of antidepressant trials and Its influence on apparent efficacy. New England Journal of Medicine 358, 252260.
Uher, R, Perlis, RH, Henigsberg, N, Zobel, A, Rietschel, M, Mors, O, Hauser, J, Dernovsek, MZ, Souery, D, Bajs, M, Maier, W, Aitchison, KJ, Farmer, A and McGuffin, P (2012 a) Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychological Medicine 42, 967980.
Uher, R, Tansey, KE, Malki, K and Perlis, RH (2012 b) Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 13, 233240.
Vrieze, E, Pizzagalli, DA, Demyttenaere, K, Hompes, T, Sienaert, P, de Boer, P, Schmidt, M and Claes, S (2013) Reduced reward learning predicts outcome in major depressive disorder. Biological Psychiatry 73, 639645.
Vuorilehto, MS, Melartin, TK and Isometsä, ET (2009) Course and outcome of depressive disorders in primary care: a prospective 18-month study. Psychological Medicine 39, 16971707.
Wakefield, JC and Schmitz, MF (2013) When does depression become a disorder? Using recurrence rates to evaluate the validity of proposed changes in major depression diagnostic thresholds. World Psychiatry 12, 4452.
Waljee, AK, Mukherjee, A, Singal, AG, Zhang, Y, Warren, J, Balis, U, Marrero, J, Zhu, J and Higgins, PD (2013) Comparison of imputation methods for missing laboratory data in medicine. BMJ Open 3, e002847.
Watson, D, Clark, LA, Weber, K, Assenheimer, JS, Strauss, ME and McCormick, RA (1995) Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. Journal of Abnormal Psychology 104, 1525.
Webb, CA, Dillon, DG, Pechtel, P, Goer, FK, Murray, L, Huys, QJ, Fava, M, McGrath, PJ, Weissman, M, Parsey, R, Kurian, BT, Adams, P, Weyandt, S, Trombello, JM, Grannemann, B, Cooper, CM, Deldin, P, Tenke, C, Trivedi, M, Bruder, G and Pizzagalli, DA (2016) Neural correlates of three promising endophenotypes of depression: evidence from the EMBARC study. Neuropsychopharmacology 41, 454463.


Type Description Title
Supplementary materials

Webb et al. supplementary material
Webb et al. supplementary material 1

 Word (303 KB)
303 KB

Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study

  • Christian A. Webb (a1), Madhukar H. Trivedi (a2), Zachary D. Cohen (a3), Daniel G. Dillon (a1), Jay C. Fournier (a4), Franziska Goer (a1), Maurizio Fava (a5), Patrick J. McGrath (a6), Myrna Weissman (a6), Ramin Parsey (a7), Phil Adams (a6), Joseph M. Trombello (a2), Crystal Cooper (a2), Patricia Deldin (a8), Maria A. Oquendo (a3), Melvin G. McInnis (a8), Quentin Huys (a9), Gerard Bruder (a6), Benji T. Kurian (a2), Manish Jha (a2), Robert J. DeRubeis (a3) and Diego A. Pizzagalli (a1)...


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed